Zoledronic acid

被引：60

作者：

Cheer S.M. ^{[1
]}

Noble S. ^{[1
]}

机构：

[1] Adis International Limited, Mairangi Bay, Auckland 10

来源：

Drugs | 2001年 / 61卷 / 6期

关键词：

Bone Resorption; Zoledronic Acid; Serum Calcium Level; Alendronic Acid; Pivotal Trial;

D O I：

10.2165/00003495-200161060-00010

中图分类号：

学科分类号：

摘要：

Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D3-induced hypercalcaemia in a rat model and calcium release in vitro. A single 5-minute intravenous infusion of zoledronic acid (4 or 8mg) was significantly more effective than a 2-hour infusion of pamidronic acid (pamidronic acid disodium, pamidronate disodium) [90mg] in normalising serum calcium levels in patients with hypercalcaemia of malignancy and resulted in a significantly longer median time to relapse (pooled analysis from 2 randomised, double-blind, parallel-group trials). There were no differences in tolerability between zoledronic acid and pamidronic acid in comparative trials; the most common events in pivotal trials were fever, anaemia, nausea, constipation and dyspnoea. Fever, hypophosphataemia and hypocalcaemia were the most common events in a small phase I trial.

引用

页码：799 / 805

页数：6

共 14 条

[1]

Green M.D., Oral bisphosphonates and malignancy, Med J Aust, 167, pp. 211-212, (1997)

[2]

Body J.J., Coleman R.E., Piccart M., Use of bisphosphonates in cancer patients, Cancer Treat Rev, 22, 4, pp. 265-287, (1996)

[3]

Body J.J., Clinical research update: Zoledronate, Cancer, 80, SUPPL., pp. 1699-1701, (1997)

[4]

Zometa International Monograph

[5]

Berenson J.R., Vescio R., Henick K., Et al., A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease, Cancer, 91, 1, pp. 144-154, (2001)

[6]

Green J.R., Moller K., Jaeggi K.A., Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound, J Bone Miner Res, 9, pp. 745-751, (1994)

[7]

Pataki A., Muller K., Green J.R., Et al., Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment, Anat Rec, 249, pp. 458-468, (1997)

[8]

Evans C.E., Braidman I.P., Effects of two novel bisphosphonates on bone cells in vitro, Bone Miner, 26, pp. 95-107, (1994)

[9]

Green J.R., Seltenmeyer Y., Jaeggi K.A., Et al., Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models, Pharmacol Toxicol, 80, pp. 225-230, (1997)

[10]

Zometa: product information

← 1 2 →